Young plasma transfusion, a procedure infusing the liquid part of young donors' blood into older people to slow aging, rests on animal research. Small studies in memory and movement disorders hinted at better daily function but no clear gain in thinking; transfusion records show no survival advantage from young donors. Risks match any donor plasma: allergic reactions, rare but serious lung injury, fluid overload. It remains experimental, human benefits unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| IgA | About 70–400 mg/dL | Absent IgA stops standard plasma use |
| ABO and Rh type, antibody screen | No established target; record type | Determines compatible plasma |
| Serum creatinine and eGFR | Creatinine about 0.6–1.3 mg/dL | Kidney impairment raises fluid-overload risk |
| NT-proBNP | Below about 125 pg/mL under age 75 and 450 pg/mL from age 75; track change from own baseline | Rising values flag heart strain |
| Ionized calcium | About 1.15–1.32 mmol/L | Low values pause exchange |
| HIV, hepatitis B and hepatitis C tests | Negative | Documents pre-exposure status |
| INR (warfarin users only) | About 0.8–1.1; warfarin users track change from own baseline | A fall signals warfarin reversal |
| hs-CRP, IL-6 and TNF-α | hs-CRP below about 5 mg/L; IL-6 and TNF-α per the laboratory's own interval; track change from own baseline | Inflammatory markers proposed to fall |
| Epigenetic clock (e.g., GrimAge) | No established target; track change from own baseline | Proposed marker of biological age |
Cadence: Baseline before the first infusion; blood pressure, heart rate, oxygen saturation and symptoms during and for 30–60 minutes after each session; ionized calcium during each exchange session; kidney and heart-strain markers after the first week; inflammatory markers, functional scales and any clock at 1 month and 3 months after the course, and every 6 months if courses are repeated